The Trump administration has introduced legislation outlining plans for deep cuts to Medicaid, possibly impacting millions of ...

The human immunodeficiency virus (HIV) market across the seven major markets (7MM), comprising the US, France, Germany, Italy ...

Nearly 220 additional participants will be randomised in Part B to determine the optimum dose of Annamycin’s ideal dose with HiDAC or HiDAC with a placebo. Credit: fizkes/Shutterstock. The European ...

Most approved GLP-1RAs are administered subcutaneously. Image credit: Getty Images / Steve Christo – Corbis A study has found that glucagon-like peptide-1 receptor agonists (GLP-1RAs) offer ...

A panel at OCT Europe touched upon where the European clinical trial industry is headed and the impact of technology and ...

NMIBC is becoming more prominent as its incidence is correlated with older age groups, with the median age being 70 when ...

The Danish multinational said that Sogroya improved the yearly growth rate in pre-pubertal children born small for ...

LEO Pharma has reported topline outcomes from the Phase IIb trial of temtokibart, a potential new treatment for atopic ...

AstraZeneca's Imfinzi, when combined with standard-of-care BCG induction and maintenance therapy, showed DFS improvement.

Vir is holding off on advancing the combination therapy to Phase III trials in hepatitis B until it secures a development ...

Johnson & Johnson (J&J) has reported new data from the Phase III ICONIC-TOTAL trial, assessing icotrokinra in treating plaque ...

Cognition Therapeutics has announced positive topline outcomes from the Phase II MAGNIFY trial of zervimesine in adult ...